Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Potential competitor for Antibe? (PLX Pharma)

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Dec 31, 2020 1:02pm

187 Views

Post# 32204179

RE:Potential competitor for Antibe? (PLX Pharma)

Looks like it's for sensitive stomachs.
Once it's in the first part of the intestine, it seems to revert back to the original problem associated with Aspirin - as higer acidity destroys the protective coating on the Aspirin.

That's just my initial impression of what I see.

I'd also like to think ATE's product is more efficient, allowing for less active ingredients due to H2S properties - and - much safer overall. IMO.

Thanks RalphRalph.

Happy New Year All !!!!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing